SCHEMBL5397479

SCHEMBL5397479

COc1ccc(CNC(=O)c2ccccc2-c2ccccc2C(=O)N(CCC(=O)O)Cc2ccccc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.61
HDAC6 Q9UBN7 2/20 0.61
TDP1 Q9NUW8 1/20 0.55
RAB9A P51151 2/20 0.53
LPAR1 Q92633 1/20 0.52
HPGD P15428 4/20 0.51
NPC1 O15118 2/20 0.50
TSHR P16473 1/20 0.50
CXCR3 P49682 1/20 0.49
ALDH1A1 P00352 1/20 0.49
TP53 P04637 1/20 0.48
GLA P06280 1/20 0.48
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.48
KMT2A Q03164 1/20 0.48
CHRNB2 P17787 1/20 0.47
CHRNB4 P30926 1/20 0.47
CHRNA3 P32297 1/20 0.47
CHRNA4 P43681 1/20 0.47
PDK1 Q15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5407093 1.00 HDAC1 (0.61) HDAC1HDAC6TDP1RAB9ALPAR1
SCHEMBL5403175 0.99 HDAC1 (0.59) HDAC1HDAC6TDP1RAB9ALPAR1
SCHEMBL5392370 0.95 HDAC1 (0.55) HDAC1HDAC6TDP1RAB9ALPAR1
SCHEMBL5403231 0.94 HDAC1 (0.55) HDAC1HDAC6TDP1RAB9ALPAR1
SCHEMBL5402486 0.94 HDAC1 (0.55) HDAC1HDAC6TDP1RAB9ALPAR1
SCHEMBL5395516 0.94 HDAC1 (0.55) HDAC1HDAC6TDP1RAB9ALPAR1
SCHEMBL5392918 0.93 RAB9A (0.65) HDAC1HDAC6TDP1RAB9ALPAR1
SCHEMBL5402275 0.93 HDAC1 (0.55) HDAC1HDAC6TDP1RAB9ALPAR1
SCHEMBL5402329 0.92 RAB9A (0.55) HDAC1HDAC6TDP1RAB9ALPAR1
SCHEMBL5398082 0.91 ALDH1A1 (0.54) HDAC1HDAC6RAB9ALPAR1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB HDAC1 2189/4885HDAC6 2386/4885TDP1 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.